Pharming Group N.V.
PHAR Nasdaq Pharmaceutical Preparations Financials FY2019–FY2025
Last close · Oct 23, 2026
$11.20
5.0%
Revenue
Total sales reported in the income statement.
$376M
26.6%
vs prior year
Operating margin
Operating income as a share of revenue.
6.9%
9.8 pts
Net income
Profit after all expenses, interest and tax.
$2.9M
Free cash flow
Cash from operations minus capital spending.
$54.0M
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
—
Market cap
Last close times the latest diluted share count, so it is approximate.
$836M
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
—
On $0.04 EPS (TTM)
What Pharming Group N.V. does
No business description yet.
- Legal name
- Pharming Group N.V.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Apr 2, 2026
- Accession · CIK
- 0001828316-26-000015
0001828316
Revenue and margins
Pharming Group N.V. had $376M of revenue in fiscal 2025, up 26.6% on the year before.
FY19
Revenue $189M
FY20
Revenue $212M
FY21
Revenue $199M
FY22
Revenue $206M
FY23
Revenue $245M
FY24
Revenue $297M
FY25
Revenue $376M
FY19
Gross 87.4%
Operating 36.0%
Net 21.4%
FCF 37.8%
FY20
Gross 88.9%
Operating 35.9%
Net 17.8%
FCF 37.2%
FY21
Gross 89.4%
Operating 6.8%
Net 8.0%
FCF 13.6%
FY22
Gross 91.5%
Operating 8.9%
Net 6.7%
FCF 10.3%
FY23
Gross 89.7%
Operating −2.2%
Net −4.3%
FCF −7.6%
FY24
Gross 88.1%
Operating −2.9%
Net −4.0%
FCF −0.9%
FY25
Gross 87.9%
Operating 6.9%
Net 0.8%
FCF 14.3%
Gross
Operating
Net
FCF
Net income and earnings per share
From fiscal 2019 to 2025, diluted EPS grew −36.3% a year. Loss periods are shown in red.
FY19
Net income $40.6M
FY20
Net income $37.7M
FY21
Net income $16.0M
FY22
Net income $13.7M
FY23
Net income −$10.5M
FY24
Net income −$11.8M
FY25
Net income $2.9M
FY19
Diluted EPS $0.60
FY20
Diluted EPS $0.55
FY21
Diluted EPS $0.23
FY22
Diluted EPS $0.19
FY23
Diluted EPS −$0.16
FY24
Diluted EPS −$0.18
FY25
Diluted EPS $0.04
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY19
Return on capital —
Return on equity 34.5%
Return on assets 15.8%
FY20
Return on capital —
Return on equity 25.1%
Return on assets 11.2%
FY21
Return on capital —
Return on equity 8.5%
Return on assets 3.9%
FY22
Return on capital —
Return on equity 6.9%
Return on assets 3.3%
FY23
Return on capital —
Return on equity −5.0%
Return on assets −2.4%
FY24
Return on capital —
Return on equity −5.4%
Return on assets −2.7%
FY25
Return on capital —
Return on equity 1.1%
Return on assets 0.6%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was $54.0M in fiscal 2025, 14.3% of revenue. Cash from operations minus capital spending.
FY19
Free cash flow $71.5M
FY20
Free cash flow $79.0M
FY21
Free cash flow $27.1M
FY22
Free cash flow $21.1M
FY23
Free cash flow −$18.7M
FY24
Free cash flow −$2.6M
FY25
Free cash flow $54.0M
FY19
Cash from operations $74.1M
Capital spending $2.6M
FY20
Cash from operations $83.6M
Capital spending $4.7M
FY21
Cash from operations $37.8M
Capital spending $10.7M
FY22
Cash from operations $22.5M
Capital spending $1.4M
FY23
Cash from operations −$17.3M
Capital spending $1.4M
FY24
Cash from operations −$1.8M
Capital spending $0.8M
FY25
Cash from operations $54.7M
Capital spending $0.7M
Cash from operations
Capital spending
Dividends, buybacks and share count
Pharming Group N.V. returned — to shareholders in fiscal 2025. The diluted share count fell 4.9%.
FY19
Dividends —
Buybacks —
FY20
Dividends —
Buybacks —
FY21
Dividends —
Buybacks —
FY22
Dividends —
Buybacks —
FY23
Dividends —
Buybacks —
FY24
Dividends —
Buybacks —
FY25
Dividends —
Buybacks —
Dividends
Buybacks
FY19
Diluted shares 0.07B
FY20
Diluted shares 0.07B
FY21
Diluted shares 0.07B
FY22
Diluted shares 0.07B
FY23
Diluted shares 0.07B
FY24
Diluted shares 0.08B
FY25
Diluted shares 0.07B
Balance sheet
Cash, debt and the ratios that show how comfortably Pharming Group N.V. can carry it.
FY19
Cash $74.3M
Debt —
FY20
Cash $205M
Debt —
FY21
Cash $192M
Debt —
FY22
Cash $207M
Debt —
FY23
Cash $61.7M
Debt —
FY24
Cash $54.9M
Debt —
FY25
Cash $145M
Debt —
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $192M | $207M | $61.7M | $54.9M | $145M |
| Interest coverage | 144.3x | 173.6x | −40.2x | −153.9x | 131.8x |
| Current ratio | 5.3x | 4.6x | 4.1x | 3.8x | 2.6x |
| Quick ratio | 4.7x | 3.9x | 3.3x | 3.0x | 2.0x |
| Total assets | $397M | $426M | $463M | $400M | $500M |
| Total liabilities | $204M | $221M | $244M | $179M | $223M |
| Shareholders' equity | $193M | $205M | $219M | $221M | $277M |
| Net debt (− = net cash) | — | — | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Net income is positive | ✓ | ✓ | ✓ | ✓ | ✕ | ✕ | ✓ |
| Cash from operations is positive | ✓ | ✓ | ✓ | ✓ | ✕ | ✕ | ✓ |
| Return on assets rose | — | ✕ | ✕ | ✕ | ✕ | ✕ | ✓ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ | ✓ | ✕ | ✓ | ✓ |
| Debt fell relative to assets | — | — | — | — | — | — | — |
| Current ratio rose | — | ✓ | ✓ | ✕ | ✕ | ✕ | ✕ |
| Share count didn't rise | — | ✕ | ✕ | ✕ | ✕ | ✕ | ✓ |
| Gross margin rose | — | ✓ | ✓ | ✓ | ✕ | ✕ | ✕ |
| Revenue rose relative to assets | — | ✕ | ✕ | ✕ | ✓ | ✓ | ✓ |
| F-score | — / 3 | 5 / 8 | 5 / 8 | 4 / 8 | 1 / 8 | 2 / 8 | 6 / 8 |
| Accruals ratio | −13.1% | −13.6% | −5.4% | −2.1% | 1.5% | −2.3% | −11.5% |
| Altman Z'' | −1.53 | 2.66 | 2.33 | 2.65 | 2.37 | 2.26 | 2.28 |
7 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $189M | $212M | $199M | $206M | $245M | $297M | $376M |
| Gross profit | $165M | $189M | $178M | $188M | $220M | $262M | $331M |
| Research and development | $31.8M | $38.5M | $70.4M | $52.5M | $68.9M | $83.1M | $100M |
| Operating income | $68.2M | $76.3M | $13.6M | $18.2M | −$5.4M | −$8.6M | $25.8M |
| Interest expense | $0.0M | $0.1M | $0.1M | $0.1M | $0.1M | $0.1M | $0.2M |
| Pretax income | $52.3M | $44.1M | $23.1M | $15.0M | −$12.0M | −$8.5M | $12.8M |
| Income tax | $11.7M | $6.3M | $7.1M | $1.3M | −$1.5M | $3.3M | $10.3M |
| Net income | $40.6M | $37.7M | $16.0M | $13.7M | −$10.5M | −$11.8M | $2.9M |
| Net income to common | — | — | — | — | −$10.5M | −$11.8M | $2.9M |
| Diluted EPS | $0.60 | $0.55 | $0.23 | $0.19 | −$0.16 | −$0.18 | $0.04 |
| Diluted shares | 0.07B | 0.07B | 0.07B | 0.07B | 0.07B | 0.08B | 0.07B |
| Cash flow | |||||||
| Cash from operations | $74.1M | $83.6M | $37.8M | $22.5M | −$17.3M | −$1.8M | $54.7M |
| Capital expenditure | $2.6M | $4.7M | $10.7M | $1.4M | $1.4M | $0.8M | $0.7M |
| Free cash flow | $71.5M | $79.0M | $27.1M | $21.1M | −$18.7M | −$2.6M | $54.0M |
| Depreciation and amortization | $5.0M | $6.1M | $6.4M | — | — | — | — |
| Stock-based compensation | $4.3M | $6.5M | $9.1M | $6.4M | $9.3M | $11.2M | $13.8M |
| Acquisitions | — | — | — | — | $0.0M | $0.0M | $57.5M |
| Balance sheet | |||||||
| Cash and short-term investments | $74.3M | $205M | $192M | $207M | $61.7M | $54.9M | $145M |
| Current assets | $119M | $263M | $249M | $278M | $316M | $278M | $299M |
| Current liabilities | $114M | $76.8M | $46.8M | $59.7M | $78.0M | $73.8M | $116M |
| Inventory | $16.2M | $21.2M | $27.3M | $42.3M | $56.8M | $55.7M | $64.9M |
| Property and equipment, net | $9.6M | $12.2M | $13.2M | $10.4M | $9.7M | $7.8M | $7.2M |
| Intangible assets | $79.4M | $94.1M | $83.8M | $75.1M | $71.3M | $61.0M | $136M |
| Total assets | $256M | $418M | $397M | $426M | $463M | $400M | $500M |
| Total liabilities | $139M | $235M | $204M | $221M | $244M | $179M | $223M |
| Shareholders' equity | $117M | $183M | $193M | $205M | $219M | $221M | $277M |
| Margins | |||||||
| Gross margin | 87.4% | 88.9% | 89.4% | 91.5% | 89.7% | 88.1% | 87.9% |
| Operating margin | 36.0% | 35.9% | 6.8% | 8.9% | −2.2% | −2.9% | 6.9% |
| EBITDA margin | 38.7% | 38.8% | 10.0% | — | — | — | — |
| Net margin | 21.4% | 17.8% | 8.0% | 6.7% | −4.3% | −4.0% | 0.8% |
| FCF margin | 37.8% | 37.2% | 13.6% | 10.3% | −7.6% | −0.9% | 14.3% |
| Returns | |||||||
| Return on capital employed | 48.2% | 22.3% | 3.9% | 5.0% | −1.4% | −2.6% | 6.7% |
| Return on equity | 34.5% | 25.1% | 8.5% | 6.9% | −5.0% | −5.4% | 1.1% |
| Return on assets | 15.8% | 11.2% | 3.9% | 3.3% | −2.4% | −2.7% | 0.6% |
| Return on tangible equity | 106.8% | 42.2% | 14.7% | 10.6% | −7.2% | −7.4% | 2.0% |
| Growth | |||||||
| Revenue growth | — | 12.0% | −6.3% | 3.4% | 19.3% | 21.1% | 26.6% |
| Net income growth | — | −6.9% | −57.6% | −14.5% | −177.1% | — | — |
| EPS growth | — | −8.3% | −58.2% | −17.4% | −184.2% | — | — |
| FCF growth | — | 10.4% | −65.7% | −22.2% | −188.9% | — | — |
| Share count change | — | 1.4% | 2.7% | 0.9% | 2.6% | 8.3% | −4.9% |
| Financial health | |||||||
| Interest coverage | — | 1,030.5x | 144.3x | 173.6x | −40.2x | −153.9x | 131.8x |
| Current ratio | 1.0x | 3.4x | 5.3x | 4.6x | 4.1x | 3.8x | 2.6x |
| Quick ratio | 0.9x | 3.1x | 4.7x | 3.9x | 3.3x | 3.0x | 2.0x |
| Capital allocation | |||||||
| Capex / revenue | 1.4% | 2.2% | 5.4% | 0.7% | 0.6% | 0.3% | 0.2% |
| Stock comp / revenue | 2.3% | 3.1% | 4.6% | 3.1% | 3.8% | 3.8% | 3.7% |
| Quality scores | |||||||
| Piotroski F-score | — | 5.0 | 5.0 | 4.0 | 1.0 | 2.0 | 6.0 |
| Altman Z'' | −1.5 | 2.7 | 2.3 | 2.7 | 2.4 | 2.3 | 2.3 |
| Accruals ratio | −13.1% | −13.6% | −5.4% | −2.1% | 1.5% | −2.3% | −11.5% |
Source: SEC EDGAR XBRL filings (CIK 0001828316). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. Per-share figures are per US-listed share (1 ADS = 10 ordinary shares). For information only — not investment advice. Check the original filings before relying on any figure.